BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ludlam WH, Anthony L. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. Adv Ther 2011;28:825-41. [PMID: 21964965 DOI: 10.1007/s12325-011-0062-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang G, Liu X, Huo Q, Lin S, Wang W, Liu C, Sha C, Liu W. Optimization and validation of the liquid chromatography coupled to tandem mass spectrometry method for assessing octreotide release from microspheres during inflammation in rabbit models. J Chromatogr B Analyt Technol Biomed Life Sci 2023;1214:123564. [PMID: 36508900 DOI: 10.1016/j.jchromb.2022.123564] [Reference Citation Analysis]
2 Ting Lim DS, Fleseriu M. Personalized Medical Treatment in Patients with Acromegaly: A Review. Endocr Pract 2022:S1530-891X(22)00004-0. [PMID: 35032649 DOI: 10.1016/j.eprac.2021.12.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 . Endokrines System und Immunmodulation. Arzneimitteltherapie in der Palliativmedizin 2022. [DOI: 10.1016/b978-3-437-23673-0.00008-2] [Reference Citation Analysis]
4 Suwabe T, Barrera FJ, Rodriguez-Gutierrez R, Ubara Y, Hogan MC. Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials. PLoS One 2021;16:e0257606. [PMID: 34559824 DOI: 10.1371/journal.pone.0257606] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Boertien TM, Drent ML, Booij J, Majoie CBLM, Stokkel MPM, Hoogmoed J, Pereira A, Biermasz NR, Simsek S, Groote Veldman R, Tanck MWT, Fliers E, Bisschop PH. The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a 68 Ga -DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of lan reotide on t umour size. BMJ Open 2020;10:e038250. [PMID: 32792446 DOI: 10.1136/bmjopen-2020-038250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Álvarez-escolá C, Venegas-moreno EM, García-arnés JA, Blanco-carrera C, Marazuela-azpiroz M, Gálvez-moreno MÁ, Menéndez-torre E, Aller-pardo J, Salinas-vert I, Resmini E, Torres-vela EM, Gonzalo-redondo MÁ, Vílchez-joya R, de Miguel-novoa MP, Halperín-rabinovich I, Páramo-fernández C, de la Cruz-sugranyes G, Houchard A, Picó-alfonso AM. ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly. Endocrinología, Diabetes y Nutrición (English ed ) 2019;66:320-329. [DOI: 10.1016/j.endien.2019.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Álvarez-Escolá C, Venegas-Moreno EM, García-Arnés JA, Blanco-Carrera C, Marazuela-Azpiroz M, Gálvez-Moreno MÁ, Menéndez-Torre E, Aller-Pardo J, Salinas-Vert I, Resmini E, Torres-Vela EM, Gonzalo-Redondo MÁ, Vílchez-Joya R, de Miguel-Novoa MP, Halperín-Rabinovich I, Páramo-Fernández C, de la Cruz-Sugranyes G, Houchard A, Picó-Alfonso AM; ACROSTART Study Group. ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly. Endocrinol Diabetes Nutr (Engl Ed) 2019;66:320-9. [PMID: 30773338 DOI: 10.1016/j.endinu.2018.12.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zhao Y, Peng L, Li X, Zhang Y. Expression of somatostatin and its receptor 1-5 in endometriotic tissues and cells. Exp Ther Med 2018;16:3777-84. [PMID: 30405748 DOI: 10.3892/etm.2018.6730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Lau SC, Abdel-Rahman O, Cheung WY. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors. Med Oncol 2018;35:123. [PMID: 30078166 DOI: 10.1007/s12032-018-1189-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
10 Tadman M, Charlton P, Jafar-Mohammadi B, Talbot D, Grossman AB. INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE. Endocr Pract 2018;24:189-94. [PMID: 29466059 DOI: 10.4158/EP-2017-0137] [Reference Citation Analysis]
11 Endokrines System und Immunmodulation. Arzneimitteltherapie in der Palliativmedizin 2018. [DOI: 10.1016/b978-3-437-23672-3.00008-1] [Reference Citation Analysis]
12 Yau H, Kinaan M, Quinn SL, Moraitis AG. Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives. Biologics. 2017;11:115-122. [PMID: 29255345 DOI: 10.2147/btt.s108818] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
13 Pivonello R, Muscogiuri G, Holder G, Paul M, Sarp S, Lesogor A, Jordaan P, Eisinger J, Colao A. Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies. Endocrine 2018;60:65-72. [PMID: 29116540 DOI: 10.1007/s12020-017-1448-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
14 Chan DL, Ferone D, Albertelli M, Pavlakis N, Segelov E, Singh S. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. Endocrine. 2017;57:366-375. [PMID: 28726183 DOI: 10.1007/s12020-017-1360-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
15 Neuzillet C, de Mestier L, Rousseau B, Mir O, Hebbar M, Kocher HM, Ruszniewski P, Tournigand C. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. Pharmacol Ther 2018;181:49-75. [PMID: 28723416 DOI: 10.1016/j.pharmthera.2017.07.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
16 Pavel M, Becerra C, Grosch K, Cheung W, Hasskarl J, Yao J. Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANT-2 trial. Clin Pharmacol Ther 2017;101:462-8. [DOI: 10.1002/cpt.559] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
17 Grooteman KV, van Geenen EJ, Drenth JP. Multicentre, open-label, randomised, parallel-group, superiority study to compare the efficacy of octreotide therapy 40 mg monthly versus standard of care in patients with refractory anaemia due to gastrointestinal bleeding from small bowel angiodysplasias: a protocol of the OCEAN trial. BMJ Open 2016;6:e011442. [PMID: 27619827 DOI: 10.1136/bmjopen-2016-011442] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
18 Somatostatin (growth hormone release-inhibiting hormone) and analogues. Meyler's Side Effects of Drugs 2016. [DOI: 10.1016/b978-0-444-53717-1.01459-1] [Reference Citation Analysis]
19 Akhlaghi Y, Ghaffari S, Attar H, Alamir Hoor A. A rapid hydrolysis method and DABS-Cl derivatization for complete amino acid analysis of octreotide acetate by reversed phase HPLC. Amino Acids 2015;47:2255-63. [DOI: 10.1007/s00726-015-1999-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
20 Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review. World J Gastroenterol 2015; 21(6): 1945-1955 [PMID: 25684964 DOI: 10.3748/wjg.v21.i6.1945] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 62] [Article Influence: 7.0] [Reference Citation Analysis]
21 Hopkins RL. Pituitary Tumors: Viewpoint— Medical Therapy. Principles and Practice of Stereotactic Radiosurgery 2015. [DOI: 10.1007/978-1-4614-8363-2_29] [Reference Citation Analysis]
22 Endokrines System und Immunmodulation. Arzneimitteltherapie in der Palliativmedizin 2015. [DOI: 10.1016/b978-3-437-23671-6.00008-0] [Reference Citation Analysis]
23 Carlucci G, Selvaggi F, Sulpizio S, Bassi C, Carlucci M, Cotellese R, Ferrone V, Innocenti P, Locatelli M. Combined derivatization and high-performance liquid chromatography with fluorescence and ultraviolet detection for simultaneous analysis of octreotide and gabexate mesylate metabolite in human pancreatic juice samples: HPLC analysis of octreotide and gabexate mesylate in pancreatic juice. Biomed Chromatogr 2015;29:911-7. [DOI: 10.1002/bmc.3373] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
24 Rossi RE, Massironi S, Conte D, Peracchi M. Therapy for metastatic pancreatic neuroendocrine tumors. Ann Transl Med 2014;2:8. [PMID: 25332984 DOI: 10.3978/j.issn.2305-5839.2013.03.01] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
25 Espinosa de los Monteros AL, Carrasco CA, Albarrán AA, Gadelha M, Abreu A, Mercado M. The role of primary pharmacological therapy in acromegaly. Pituitary 2014;17 Suppl 1:S4-10. [PMID: 24166706 DOI: 10.1007/s11102-013-0530-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
26 Neuzillet C, Hentic O, Raymond E, Ruszniewski P. Advances with Somatostatin Analogs in Neuroendocrine Tumors; The Promise of Radionuclides in Neuroendocrine Tumors. Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract 2014. [DOI: 10.1007/978-2-8178-0430-9_4] [Reference Citation Analysis]
27 Capron A, Destree J, Maiter D, Wallemacq P. Validation of a rapid liquid chromatography–tandem mass spectrometric assay for the determination of octreotide plasma concentrations. Clinical Biochemistry 2014;47:139-41. [DOI: 10.1016/j.clinbiochem.2013.07.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
28 Dalan R, Leow MK. Miscellaneous hormones. A worldwide yearly survey of new data in adverse drug reactions and interactions 2014. [DOI: 10.1016/b978-0-444-62635-6.00043-7] [Reference Citation Analysis]
29 Störmann S, Schopohl J. Emerging drugs for acromegaly. Expert Opin Emerg Drugs 2014;19:79-97. [PMID: 24400774 DOI: 10.1517/14728214.2014.875529] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
30 Chan MM, Chan MM, Mengshol JA, Fish DN, Chan ED. Octreotide. Chest 2013;144:1937-45. [DOI: 10.1378/chest.13-0382] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
31 van Varsseveld NC, Bisschop PHLT, Biermasz NR, Pereira AM, Fliers E, Drent ML. A long-term follow-up study of eighteen patients with thyrotrophin-secreting pituitary adenomas. Clin Endocrinol 2014;80:395-402. [DOI: 10.1111/cen.12290] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
32 Keskin O, Yalcin S. A review of the use of somatostatin analogs in oncology. Oncotargets Ther. 2013;6:471-483. [PMID: 23667314 DOI: 10.2147/ott.s39987] [Cited by in Crossref: 13] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
33 Mathioudakis N, Salvatori R. Management options for persistent postoperative acromegaly. Neurosurg Clin N Am 2012;23:621-38. [PMID: 23040748 DOI: 10.1016/j.nec.2012.06.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
34 . Current world literature. Curr Opin Endocrinol Diabetes Obes 2012;19:328-37. [PMID: 22760515 DOI: 10.1097/MED.0b013e3283567080] [Reference Citation Analysis]
35 Davies DE, Wren T, MacLachlan SM. Octreotide infusion for malignant duodenal obstruction in a 12-year-old girl with metastatic peripheral nerve sheath tumor. J Pediatr Hematol Oncol 2012;34:e292-4. [PMID: 22735881 DOI: 10.1097/MPH.0b013e318257dd4c] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]